Key Highlights

  • Nautilus Biotechnology (NASDAQ:NAUT) traded about 11.42% lower, near USD 2.87, in early trading on Monday, October 26, 2026, from an opening of USD 3.24 on Friday, October 23, 2026.
  • The company is expected to report third-quarter results before the open on Tuesday, October 27, 2026, with a call at 8:30 a.m. ET and consensus estimates of a loss of USD 0.14 per share.
  • Consensus revenue is about USD 0.21 million, and the shares carry a market value near USD 412 million with a one-year range of USD 0.84 to USD 4.31.
  • The company has not issued a release explaining the move, so the fall may reflect positioning ahead of earnings after a sharp rally.

A Pre-Earnings Pullback After a Strong Run

Nautilus Biotechnology (NASDAQ:NAUT) develops a platform for measuring proteins, the molecules that carry out most functions in cells, and its shares traded about 11.42% lower, near USD 2.87, in early trading on Monday, October 26, 2026. The company has not issued a release explaining the move. Published data show the shares opened at USD 3.24 on Friday, October 23, 2026, against a one-year low of USD 0.84 and a high of USD 4.31. The 50-day moving average of USD 1.39 and the 200-day average of USD 1.90 sit well below the price, which indicates a steep advance in recent weeks. Third-quarter results are due before the open on Tuesday, October 27, 2026.

Why Earnings Timing Can Drive a Pre-Revenue Stock

Nautilus Biotechnology (NASDAQ:NAUT) has almost no revenue, so its quarterly report is judged on cash burn, platform milestones and launch timing, not on sales. Consensus calls for a loss of USD 0.14 per share on revenue of about USD 0.21 million, compared with a loss of USD 0.11 and revenue of USD 0.19 million in the quarter reported on July 27, 2026. Full-year consensus is a loss of USD 0.52 per share. When a stock trades far above its moving averages, holders often reduce exposure before an event, and that selling can produce a fall of this size without news. Roth Capital rated the shares buy with a USD 3.50 target on September 29, 2026, and Leerink Partners rated them outperform with a USD 4.00 target on September 9, 2026.

Risks and What to Watch

The first risk for Nautilus Biotechnology (NASDAQ:NAUT) is a wider loss or a delayed platform timetable, which could unwind the recent rise. The second is funding, since a company with minimal revenue relies on its cash balance, and the data available did not state the latest figure. The third is valuation: with the price close to the Roth target, further analyst support may depend on technical milestones. A weak market for small biotechnology companies adds pressure. Investors should watch the results and call on Tuesday, October 27, 2026, the cash and runway disclosure, any change to analyst targets, and the Federal Reserve decision on Wednesday, October 28, 2026.

Where Things Stand

The answer is that Nautilus Biotechnology (NASDAQ:NAUT) fell 11.42% in early trading on Monday, October 26, 2026 with no company release on the day, most plausibly as holders trimmed positions ahead of earnings after a rally well above the 50-day average. That explanation is an inference from the timing and the price pattern. The next catalysts are the third-quarter results on October 27, 2026 at 8:30 a.m. ET and the Federal Reserve decision on October 28, 2026. Estimates and analyst targets are not guarantees, and this is not investment advice.